Long-Acting Injectables and the Pursuit of an HIV Cure: A New Era in Prevention and Treatment
A paradigm shift is underway in the fight against HIV, moving beyond daily oral medications toward long-acting injectables and, ultimately, a cure. While combination antiretroviral therapies (ART) have dramatically transformed HIV from a death sentence to a manageable chronic condition, significant hurdles remain – including access, adherence, and the persistent challenge of viral reservoirs. New research suggests that long-acting injectables, coupled with continued investment in curative strategies, offer the most promising path toward controlling and potentially eradicating the virus.
The Evolution of HIV Treatment: From Crisis to Control
For decades, ART has been the cornerstone of HIV management. When taken as prescribed, ART suppresses viral replication, preventing disease progression and transmission, and enabling individuals with HIV to live long, productive lives. Globally, these therapies have played a pivotal role in reversing the course of the HIV epidemic. However, ART is not without its limitations. “ART is not a panacea for HIV control,” experts acknowledge, citing high barriers to access and adherence, particularly with daily oral regimens. Furthermore, ART does not cure HIV, nor does it fully restore immune function, and carries a lifelong risk of medication resistance.
Addressing Access and Adherence: A Critical Need
Improving the real-world utility of existing therapies requires tackling systemic barriers to access and adherence. Successful global health initiatives would ideally eliminate HIV transmission and mortality by eliminating stigma, implementing regionally adapted programs, enhancing disease surveillance, and ensuring affordable, lifelong access to healthcare. However, these systemic impediments are unlikely to disappear entirely. Therefore, the most impactful advances will come from therapeutic developers who understand the complex challenges faced by those at risk of HIV and develop interventions effective in real-world contexts.
Long-Acting Injectables: A Game Changer in HIV Prevention
Recent breakthroughs in long-acting injectable ART represent a significant step forward. Compared to daily pills, these injectables offer several advantages: reduced side effects, a lower risk of resistance, increased convenience, and decreased visibility of treatment – all particularly meaningful for high-risk populations facing stigma and logistical obstacles.
The PURPOSE 1 trial, sponsored by Gilead Sciences and conducted in South Africa and Uganda, demonstrated the remarkable efficacy of a twice-yearly injection of lenacapavir for HIV prevention. In a study of 5,338 cisgender women, lenacapavir resulted in zero HIV infections, compared to 16 infections among those taking daily oral PrEP. This outcome underscores how thoughtfully designed therapeutic options can dramatically improve adherence and real-world outcomes by eliminating the daily pill burden and reducing social and structural barriers.
Beyond Suppression: The Quest for a Cure
While long-acting injectables represent a substantial improvement over oral ART, they still share the inherent limitations of suppressive therapies. Ongoing access, adherence, and monitoring remain crucial, and the risk of treatment resistance persists, particularly in settings with global treatment disparities. Moreover, long-term ART use may be associated with side effects, including inflammation and increased risk of cardiovascular and neurocognitive disorders.
These realities highlight the urgent need for continued research into preventative modalities that interrupt transmission at the population level and curative strategies that eliminate viral reservoirs. Areas of growing interest include mRNA-based vaccines designed to train the immune system to recognize diverse HIV strains and combination therapies aimed at exposing and eliminating latent reservoirs of HIV-infected cells. .
Developing Interventions for Real-World Impact
The true value of any anti-HIV intervention will be determined by its ability to simplify and improve HIV control efforts in the most affected regions and populations. Establishing this value during clinical development is challenging, as existing therapies are already highly effective when taken as prescribed.
Instead of relying on idealized trial conditions, developers should prioritize trials that reflect the lived realities of target populations. This requires understanding which populations are disproportionately affected and implementing trials in environments that mirror the social, logistical, and structural challenges they face. The five PURPOSE trials for lenacapavir serve as a valuable model, providing a comprehensive and diverse effort in investigational HIV PrEP.
The Power of Partnership
Achieving meaningful diversity in trial populations and designing trials that account for population-specific constraints requires authentic partnerships with affected communities. Their input should inform study design, recruitment strategies, and cultural alignment, ensuring that the evidence generated is rigorous and broadly applicable. Post-approval, these partnerships will be critical for integrating emerging therapies into existing public health systems.
Developers who embed community collaboration into their research, development, and commercialization frameworks will be best positioned to demonstrate and realize the full therapeutic potential of new anti-HIV interventions. The future of HIV control hinges not only on scientific innovation but also on a commitment to equity, access, and collaboration.
